Alnylam Signs Billion Dollar RNAi Deal With Roche

Best path to build value for shareholders is to maintain independent, focused and hungry biotech culture, Alnylam CEO tells “The Pink Sheet” DAILY.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet